Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERANTI: IPN10200 for prevention of episodic or chronic migraine in adults
jRCT2031250101Phase 2Recruiting
- Sponsor
- Ipsen
- Start
- Sep 2025
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of corabotase in episodic migraine and chronic migraine (3 arms), sponsored by Ipsen. Primary endpoints: Percentage of participants experiencing any adverse event, Percentage of participants with clinically significant changes from baseline in laboratory parameters and 7 more. Started Sep 2025; status: recruiting.
02
Drugs
corabotase
03
Conditions
episodic migrainechronic migraine
Beyond the preview
Go deeper on jRCT2031250101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250101.